^
Association details:
| Biomarker: | RET C634W |
|---|---|
| Cancer: | Thyroid Gland Medullary Carcinoma |
| Drug: | vepafestinib (TAS0953/HM06) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
Published date:
09/21/2023
Excerpt:
Vepafestinib also inhibited the growth of multiple lung cancer patient-derived cell lines harboring RET fusions with different N-terminal partners (CCDC6, KIF5B, TRIM33) and a RETC634W-mutation-positive MTC cell line.
DOI:
https://doi.org/10.1038/s43018-023-00630-y
